IDYA
Price
$21.10
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.85B
67 days until earnings call
PDSB
Price
$1.57
Change
-$0.08 (-4.85%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
71.76M
69 days until earnings call
Interact to see
Advertisement

IDYA vs PDSB

Header iconIDYA vs PDSB Comparison
Open Charts IDYA vs PDSBBanner chart's image
IDEAYA Biosciences
Price$21.10
Change-$0.00 (-0.00%)
Volume$15.76K
Capitalization1.85B
PDS Biotechnology
Price$1.57
Change-$0.08 (-4.85%)
Volume$1.65K
Capitalization71.76M
IDYA vs PDSB Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. PDSB commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and PDSB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (IDYA: $21.08 vs. PDSB: $1.57)
Brand notoriety: IDYA and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 45% vs. PDSB: 80%
Market capitalization -- IDYA: $1.85B vs. PDSB: $71.76M
IDYA [@Biotechnology] is valued at $1.85B. PDSB’s [@Biotechnology] market capitalization is $71.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 7 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 4 bearish.
  • PDSB’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +5.14% price change this week, while PDSB (@Biotechnology) price change was +12.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.85B) has a higher market cap than PDSB($71.8M). PDSB YTD gains are higher at: 1.227 vs. IDYA (-17.977). PDSB has higher annual earnings (EBITDA): -36.65M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. PDSB (49.8M). PDSB has less debt than IDYA: PDSB (24.7M) vs IDYA (26M). IDYA has higher revenues than PDSB: IDYA (7M) vs PDSB (0).
IDYAPDSBIDYA / PDSB
Capitalization1.85B71.8M2,571%
EBITDA-356.46M-36.65M973%
Gain YTD-17.9771.227-1,465%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash693M49.8M1,392%
Total Debt26M24.7M105%
FUNDAMENTALS RATINGS
IDYA vs PDSB: Fundamental Ratings
IDYA
PDSB
OUTLOOK RATING
1..100
1614
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
6493
SMR RATING
1..100
4597
PRICE GROWTH RATING
1..100
6058
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (39) in the Pharmaceuticals Major industry is in the same range as IDYA (61) in the null industry. This means that PDSB’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (64) in the null industry is in the same range as PDSB (93) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to PDSB’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is somewhat better than the same rating for PDSB (97) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than PDSB’s over the last 12 months.

PDSB's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as IDYA (60) in the null industry. This means that PDSB’s stock grew similarly to IDYA’s over the last 12 months.

PDSB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that PDSB’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAPDSB
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFTAX12.45N/A
N/A
Voya International High Div Low Vol A
FOCPX20.81N/A
N/A
Fidelity OTC
MSTFX11.22N/A
N/A
Morningstar International Equity
FOBAX20.08-0.06
-0.30%
Tributary Balanced Instl
CGIOX47.08-0.19
-0.40%
Calamos Growth and Income R6

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+7.84%
RXRX - PDSB
48%
Loosely correlated
+11.85%
IDYA - PDSB
44%
Loosely correlated
-2.50%
AXON - PDSB
43%
Loosely correlated
+2.76%
CRNX - PDSB
43%
Loosely correlated
+0.78%
KYMR - PDSB
43%
Loosely correlated
+1.56%
More